SML3270
QLT0267
≥98% (HPLC)
别名:
3,5-Diamino-4-(p-methoxyphenyl)hydrazonopyrazole, 4-((4-Methoxyphenyl)diazenyl)-1H-pyrazole-3,5-diamine, ILK-IN-3, KP 15792, KP-15792, KP15792, QLT 0267, QLT-0267
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C10H12N6O
化学文摘社编号:
分子量:
232.24
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[nH]1nc(c(c1N)\N=N\c2ccc(cc2)OC)N
InChI
1S/C10H12N6O/c1-17-7-4-2-6(3-5-7)13-14-8-9(11)15-16-10(8)12/h2-5H,1H3,(H5,11,12,15,16)/b14-13+
InChI key
QNRNTYHAOBVOKW-BUHFOSPRSA-N
Biochem/physiol Actions
Orally active, potent and selective integrin-linked kinase (ILK) inhibitor with anti-cancer efficacy in cultures and in vivo.
QLT0267 is an orally active, potent and selective integrin-linked kinase (ILK) inhibitor (IC50 = 26 nM; selectivity: >1000-fold over CK2, CSK, DNA-PK, PIM1, PKB/AKT, PKC, >100-fold over ERK1, GSK3β, LCK, PKA, p70S6K, and RSK1/QLT, >10-fold over CDK1/2/5) that inhibits ILK-dependent cellular signaling (IC50 in 2h = 1 μM against 20 nM EGF-induced pAKT Ser473 phosphorylation in Hth74 cells). QLT0267 treatment causes thyroid cancer cell cycle arrest and apoptosis, leading to anti-proliferation efficacy in cultures (IC50 <6 μM; NPA187, DRO, and K4 cell lines) and in mice in vivo (DRO xenografts-derived tumor growth; 50-100 mg/kg via daily p.o.).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable